Guidelines for use of margetuximab: key information and precautions

Margetuximab is an anti-HER2 monoclonal antibody, mainly used to treat HER2-positive advanced or metastatic breast cancer. The drug is designed to combine the targeting HER2 effect of trastuzumab (Trastuzumab) while optimizing span>Fc segment structure, thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) and improving the immune system's ability to attack tumor cells. Before using this drug, patients should read the drug instructions carefully and follow the doctor's instructions to ensure safe and effective treatment.

1. Key information in drug instructions

Margetuximab package inserts typically include the following key elements:

Indications: This drug is suitable for patients with HER2 positive advanced or metastatic breast cancer. It is usually used in combination with chemotherapy drugs (such as paclitaxel) and is mainly used for patients who have progressed after receiving at least two anti-HER2 treatments (including trastuzumab and pertuzumab).

Dose and usage: The recommended dose is usually 15mg/kg as an intravenous infusion once every 3 weeks. The first infusion should be given slowly (approximately 120 minutes), and subsequent infusions can be shortened to 30-60 minutes.

Pharmacokinetics: The half-life of the drug is long and it usually takes several weeks to be completely eliminated, so the dosage needs to be adjusted carefully.

Adverse reactions: The most common adverse reactions include infusion-related reactions, fatigue, nausea, diarrhea, anemia, and leukopenia. Serious adverse reactions may involve cardiotoxicity and immune-related side effects.

Contraindications: Use should be prohibited in patients who are allergic to the drug or its ingredients. Patients with severe heart disease also need to carefully consider whether it is suitable for use.

2. Special precautions when taking margetuximab

When using margetuximab, patients and doctors should pay special attention to the following points:

(1) Heart function monitoring: HER2Targeted therapies (such as trastuzumab and margituximab) may increase the risk of cardiotoxicity, including decreased left ventricular ejection fraction (LVEF) and congestive heart failure. Therefore, patients need to regularly check their cardiac function (such as echocardiography) before, during and after treatment. Patients with a history of heart disease, irregular heartbeat, or high blood pressure should be carefully evaluated for suitability for this drug.

(2) Infusion-related reactions: Intravenous infusion of margituximab may cause infusion-related reactions (IRR), usually manifesting as fever, chills, rash, hypotension or hypertension, etc. Most reactions occur during the first infusion, so it is recommended to closely monitor the patient's condition during the first infusion and use antihistamines or corticosteroids to prevent reactions if necessary. If severe infusion reactions (such as acute allergic reactions) occur, the infusion should be stopped immediately and appropriate treatment should be given.

(3) Infection risk and immune monitoring: Because this drug affects the immune system, long-term use may increase the risk of infection. Patients should pay close attention to fever, cough, sore throat, skin ulcers or other symptoms of infection, and receive anti-infective treatment if necessary. In addition, immunosuppressed patients (such as those with AIDS or those taking long-term immunosuppressants) need to be particularly careful to prevent their condition from worsening.

(4) Medication during pregnancy and lactation: Margetuximab may cause severe reproductive toxicity to the fetus, so pregnant women or women planning to become pregnant should conduct a pregnancy test before use and take effective contraceptive measures (continue contraception for at least 7 months after treatment). In addition, there are insufficient studies to confirm whether this drug is excreted in breast milk, so breast-feeding women should avoid its use.

3. Possible drug interactions

Although margituximab mainly exerts its anti-tumor effect by enhancing the ADCC effect in the Fc segment, it may affect the efficacy or increase side effects when combined with certain chemotherapy drugs or immunosuppressants. For example:

When combined with paclitaxel (Paclitaxel), the anti-tumor effect can be enhanced, but you need to be alert to the risk of peripheral neuropathy;

Combined use with trastuzumab may result in excessiveHER2 inhibition and increase the possibility of cardiotoxicity;

When used in combination with immune checkpoint inhibitors (such asPD-1/PD-L1monoclonal antibodies), the immune response may be further enhanced, but autoimmune adverse reactions (such as rash, enteritis, etc.) need to be monitored.

Margituximab isHER2The new generation of monoclonal antibodies in the treatment of positive breast cancer has a mechanism of action that optimizes the immune system's ability to attack tumor cells and has certain advantages in drug-resistant patient groups. However, the drug still carries risks such as cardiotoxicity, infusion-related reactions, and immune system effects. Therefore, during use, it is necessary to closely monitor cardiac function, pay attention to infusion management, be alert to the risk of infection, and ensure that patients take contraceptive measures before and after use. Patients should fully communicate with their doctors before treatment to understand the efficacy, risks and precautions of the drug to ensure safe and effective treatment.

Reference materials:https://www.margenza.com/